RxDoctor Payments Data

Mark Henderson, DO

Family Medicine · Lincoln, NENPI 1760902498

Payments from drug & device makers

$1,320in general payments, 2019–2025

Across 71 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$242
  • Merck$192
  • AstraZeneca$187
  • Lilly USA, LLC$124
  • Novo Nordisk$114
  • Corcept Therapeutics$81
  • plus $380 from 12 others

What the payments were for

  • Food & beverage$1,320100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,320 in reported general payments places this provider in the 65th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$6,418
Medicare patients
42
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$96,026
OzempicSemaglutide68$70,281
JardianceEmpagliflozin57$68,522
TrulicityDulaglutide56$58,580
MounjaroTirzepatide49$54,966
FarxigaDapagliflozin Propanediol38$44,841
Breztri AerosphereBudesonide/Glycopyr/Formoterol51$32,111
VraylarCariprazine Hcl14$30,875
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$28,770
XareltoRivaroxaban27$25,652
ProliaDenosumab12$20,866
JanuviaSitagliptin Phosphate15$11,855
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,960
Duloxetine Hcl74$5,777
Aripiprazole20$4,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$124$113,545105 claims
PfizerEliquis$15$96,02682 claims
AstraZenecaFarxiga, Breztri Aerosphere$187$76,95289 claims
Novo NordiskOzempic$114$70,28168 claims
AbbVieVraylar$242$30,87514 claims
GSKTrelegy Ellipta$16$28,77035 claims
AmgenProlia$54$20,86612 claims
MerckJanuvia$192$11,85515 claims
Sanofi-aventis U.S. LLCLantus$19$1,36423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →